Answers are grounded in this paper and cite their sources.
BACKGROUND: The COVID-19 pandemic affected healthcare management for people with multiple sclerosis (PwMS), leading to alterations in disease-modifying therapies (DMTs) due to concerns about COVID-19 outcomes and vaccine efficacy. OBJECTIVES: To compare DMT prescription patterns in PwMS before, during, and after the COVID-19 pandemic. METHODS: PwMS from the German MS Register, between 2019 and 2024, either newly diagnosed (Cohort A) or who discontinued or switched DMT (Cohort B), were analyzed over a follow-up period of 3 months. Data from the pre-pandemic period were compared to early-, late-, and post-pandemic periods. DMTs were categorized as medium efficacy (meDMT) or high efficacy (heDMT). RESULTS: In Cohort A (n = 1810), pre-pandemic 46% had no DMT within 3 months of diagnosis, 39% received meDMT, and 15% heDMT (7.5% B cell-depleting therapies (BCD)). heDMT use increased during later periods ("early" 19%, "late" 29%, "post" 41%), with a shift toward BCD. In cohort B (n = 4246), pre-pandemic 47% paused DMT, 19% switched to meDMT, and 34% to heDMT (17% BCD). heDMT use also rose during the pandemic ("early" 37%, "late" 47%, "post" 48%), with increased BCD use. CONCLUSIONS: There were no delays in DMT initiation or resumption during the pandemic with a notable increase in heDMT and BCD use, reflecting growing confidence in these treatment options.
No takes yet. Share an insight, caveat, or question.
Konitsioti et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: